IDEXX Laboratories Investor Presentation — August 2018

Document content

1 © 2018 IDEXX Laboratories, Inc. All rights reserved.

IDEXX Growth Strategy

Jonathan Ayers, Chairman and CEO

IDEXX Investor Day I August 15, 20182 © 2018 IDEXX Laboratories, Inc. All rights reserved.Safe Harbor Disclaimer

The following information contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward -looking

statements are based on management ’s current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are

subject to risks, uncertainties, assumptions and other important factors. You are cautioned not to put undue reliance on such forward -looking statements because

actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United State s securities laws contain discussions

of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward -looking

statements, whether as a result of new information, future events or otherwise. You are advised to review the Company ’s filings with the United States Securities

and Exchange Commission (which are available from the SEC ’s EDGAR database at www.sec.gov and via the Company ’s website at www.idexx.com ).

We refer in this presentation to 2018 outlook communicated on August 1, 2018; these references speak only as of August 1, 201 8 and shall not be deemed to be a

reiteration or affirmation of the guidance or an indication that our expectations have not changed since that time.

Non-GAAP Financial Measures

In this presentation, we refer to some non -GAAP financial measures. For a reconciliation to the most comparable GAAP financial m easures, we refer you to our

footnotes and the Appendix to this presentation, which also refer to our Definitive Proxy Statement filed March 29, 2018 and theCompany's Annual Report on Form

10-K for the year ended December 31, 2017, both available at www.idexx.com/investors .

Please refer to additional footnotes in the Appendix.

3 © 2018 IDEXX Laboratories, Inc. All rights reserved.IDEXX –Expanding Opportunity to Advance Pet Care

▪Strong market growth with favorable

▪Enduring recurring revenue model

▪Global leadership with wide

▪Expanding commercial model driving

adoption of an elevated standard of

▪Accelerated organic growth of CAG

Diagnostics Recurring Revenue4 © 2018 IDEXX Laboratories, Inc. All rights reserved.The Core Business Model Consists of Profitable Recurring Revenue